Controlled attenuation parameter for the diagnosis of steatosis in non‐alcoholic fatty liver disease

Controlled attenuation parameter (CAP) evaluated with transient elastography (FibroScan) is a recent method for non‐invasive assessment of steatosis. Its usefulness in non‐alcoholic fatty liver disease (NAFLD) is unknown. We prospectively investigated the performance of CAP for the diagnosis of steatosis in NAFLD, factors associated with discordances between CAP and steatosis grades, and relationships between CAP and clinical or biological parameters.

[1]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.

[2]  F. Nascimbeni,et al.  Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease , 2014, Alimentary pharmacology & therapeutics.

[3]  V. de Lédinghen,et al.  Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. , 2014, Journal of hepatology.

[4]  Youming Li,et al.  Prevalence and Risk Factors for the Development of Nonalcoholic Fatty Liver Disease in a Nonobese Chinese Population: the Zhejiang Zhenhai Study , 2013, The American Journal of Gastroenterology.

[5]  V. Wong,et al.  Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease , 2012, The American Journal of Gastroenterology.

[6]  D. Torres,et al.  Features, diagnosis, and treatment of nonalcoholic fatty liver disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  J. Vergniol,et al.  Non‐invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[8]  A. Pollett,et al.  Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[9]  Michael Charlton,et al.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. , 2012, Gastroenterology.

[10]  L. Sandrin,et al.  The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. , 2012, Clinics and research in hepatology and gastroenterology.

[11]  Paolo Crosignani,et al.  Fatty liver index and mortality: The cremona study in the 15th year of follow‐up , 2011, Hepatology.

[12]  V. de Lédinghen,et al.  Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. , 2010, Ultrasound in medicine & biology.

[13]  A. McCullough,et al.  Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. , 2009, Journal of hepatology.

[14]  Anna Castiglione,et al.  The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population , 2006, BMC gastroenterology.

[15]  F. Chan,et al.  Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non‐alcoholic fatty liver disease , 2006, Alimentary pharmacology & therapeutics.

[16]  T. Saibara,et al.  7. 非アルコール性脂肪肝炎 (NASH) の診断と治療 , 2006 .

[17]  V. Wong,et al.  Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[19]  Erick M Remer,et al.  The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[20]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[21]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.